Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive lung disease characterized by
progressive lung scarring and the histological picture of usual interstitial pneumonia (UIP). It …

Interstitial lung disease (ILD) is an increasingly recognized complication of rheumatoid
arthritis (RA) and is associated with significant morbidity and mortality. In addition …

Background At present, no approved pharmacotherapies are available for unclassifiable
interstitial lung disease (ILD), which is characterised by progressive fibrosis of the lung. We …

Pirfenidone (PFD) is a pharmacological compound with therapeutic efficacy in idiopathic
pulmonary fibrosis. It has been chiefly characterized as an antifibrotic agent, although it was …

Pirfenidone is one of two approved therapies for the treatment of idiopathic pulmonary
fibrosis (IPF). Randomised controlled clinical trials and subsequent post hoc analyses have …

Background The benefit of sildenafil in patients with advanced idiopathic pulmonary fibrosis
(IPF) at risk of poor outcomes from pulmonary hypertension, whether already present or …

Abstract Background: RECAP (NCT00662038) was an open-label extension study in
patients with idiopathic pulmonary fibrosis (IPF) who completed either the Assessment of …

Background Nintedanib is an approved therapy for idiopathic pulmonary fibrosis (IPF). Some
patients treated with nintedanib experience weight loss. Exploratory data suggest that low …

Idiopathic pulmonary fibrosis (IPF) is characterised by unpredictable disease course and
poor survival. After the introduction of novel antifibrotic drugs, the prognosis of patients with …

Ethnopharmacological relevance Pulmonary fibrosis (PF) is a chronic, debilitating and often
lethal lung disorder. Despite the molecular mechanisms of PF are gradually clear with …